Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Relay Therapeutics, Inc. (RLAY) filed a Current Report on Form 8-K on May 5, 2026. The filing announces the company's financial results for the quarter ended March 31, 2026. The full details of these results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the accompanying press release (Exhibit 99.1), which is not included in the source text.
Material Changes
No specific material changes versus the prior comparable period are described in the filing text. The document serves as a notification of the results announcement rather than a detailed financial analysis.
Guidance, Outlook, and Risks
The filing does not provide specific guidance, outlook, management commentary, or risk factors within the text of the 8-K itself. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the press release.
- Check for any updates on clinical trial progress or pipeline milestones mentioned in the full announcement.
- Confirm if the company provided updated full-year 2026 financial guidance in the press release.